SUPERA S-45-120-120-P6 (UDI 08975370026276)Recalls & reported problems
Abbott Vascular Inc. · Supera Peripheral Stent System 4.5 mm x 120 mm x 120 cm 6 F · Class 3 · Implant
All models of SUPERA (55)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 4
- Deaths reported
- 0
- Injuries reported
- 3
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 4 adverse event reports that list this exact device (DI 08975370026276), received between Aug 16, 2016 and Apr 30, 2018 — classified as 3 injuries, 1 malfunction.
The most frequently reported specific device problem is “Detachment Of Device Component” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem2
- Detachment Of Device Component1
- Difficult or Delayed Positioning1
- Difficult to Remove1
- Improper or Incorrect Procedure or Method1
- Material Deformation1
- Physical Resistance1
Patient problems
- Claudication1
- Foreign Body In Patient1
- No Consequences Or Impact To Patient1
- Pain1
- Stenosis1
- Thrombosis1
Recent adverse event reports
The 4 most recent of 4 reports, in the reporter's own words as published by the FDA.
MalfunctionApr 30, 2018Difficult to Remove; Physical Resistance
IT WAS REPORTED THAT THE PROCEDURE WAS TO TREAT A CALCIFIED LESION IN THE DISTAL SUPERFICIAL FEMORAL ARTERY (SFA). A NON-ABBOTT EMBOLIC PROTECTION FILTER AND GUIDE WIRE WERE ADVANCED TO THE LESION AND THE 4.5X120MM SUPERA SELF EXPANDING STENT SYSTEM WAS ADVANCED OVER THE WIRE. RESISTANCE WAS MET ADVANCING THE SUPERA DEVICE DUE TO THE ANATOMY AND THE GUIDE WIRE KEPT BACKING OUT AND MOVING. THERE WAS NO RESISTANCE ADVANCING THE SUPERA OVER THE GUIDE WIRE. THE SUPERA WAS ADVANCED TO THE LESION AND DURING DEPLOYMENT, THE GUIDE WIRE MOVED BACK AND THE FILTER WAS PULLED INTO THE NOSECONE OF THE SUPERA AND BECAME STUCK. THE STENT WAS ABLE TO BE SUCCESSFULLY DEPLOYED. THE SUPERA WAS REMOVED WITH THE FILTER STILL IN THE NOSECONE. THERE WAS NO CLINICALLY SIGNIFICANT DELAY IN THE PROCEDURE AND NO ADVERSE PATIENT EFFECTS. NO ADDITIONAL INFORMATION WAS PROVIDED.
Patient problems: No Consequences Or Impact To Patient
MAUDE report 7473998 ↗InjuryNov 2, 2016Detachment Of Device Component; Difficult or Delayed Positioning; Improper or Incorrect Procedure or Method; Material Deformation
SUBSEQUENT TO THE INITIAL FILED MEDWATCH REPORT, A USER FACILITY MEDWATCH REPORT WAS RECEIVED ON (B)(6) 2016 AND STATES: RIGHT SUPERFICIAL FEMORAL ARTERY (SFA) WAS HEAVILY CALCIFIED. CARDIOLOGIST STENTED THE RIGHT SFA WITH A SUPERA STENT SYSTEM. AFTER THE STENT WAS DEPLOYED, THE DELIVERY DEVICE TIP CAME LOOSE AND WAS WEDGED BETWEEN THE LESION INSIDE THE STENT WHILE REMOVING THE DEVICE. MULTIPLE ATTEMPTS WERE MADE TO RETRIEVE THE TIP WITH VARIOUS GUIDE WIRES, AND SNARE AND BALLOONS. WHAT WAS THE ORIGINAL INTENDED PROCEDURE? ABDOMINAL AORTOGRAPHY AND SELECTIVE RIGHT ILIAC ANGIOGRAPHY AND RUNOFF. SUCCESSFUL ORBITAL ATHERECTOMY OF THE RIGHT SUPERFICIAL FEMORAL ARTERY. RIGHT SUPERFICIAL FEMORAL ARTERY SELF-EXPANDING SUPERA STENT, 4.5X120. DEVICE USAGE PROBLEM: DEVICE FAILED (E.G. BROKE, COULDN'T GET IT TO WORK OR STOPPED WORKING). NO ADDITIONAL INFORMATION WAS PROVIDED.
Patient problems: Foreign Body In Patient
MAUDE report 6074350 ↗InjurySep 23, 2016Adverse Event Without Identified Device or Use Problem
IT WAS REPORTED THAT ON (B)(6) 2016, 5 SUPERA STENTS WERE IMPLANTED IN THE PROXIMAL POPLITEAL TO THE SUPERFICIAL FEMORAL ARTERY (SFA) WITHOUT REPORTED ISSUE. THE PATIENT WAS PROVIDED ASPIRIN AND PLAVIX. ON (B)(6) 2016, THE PATIENT PRESENTED TO THE HOSPITAL. THE SAME LEG CONTAINING THE IMPLANTED SUPERA STENTS WAS COLD AND PAINFUL. PER ANGIOGRAM, A BLOOD CLOT WAS NOTED IN ALL 5 STENTS, A TOTAL OCCLUSION. THE PATIENT WAS HOSPITALIZED AND BALLOON ANGIOPLASTY WAS PERFORMED USING A DRUG ELUTING BALLOON. TISSUE PLASMINOGEN ACTIVATOR (TPA) WAS PROVIDED OVERNIGHT. THE EVENT RESOLVED WITHOUT SEQUELA. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.
Patient problems: Claudication; Thrombosis
MAUDE report 5975399 ↗InjuryAug 16, 2016Adverse Event Without Identified Device or Use Problem
IT WAS REPORTED THAT ON (B)(6) 2015 THREE SUPERA STENTS (4.5 X 120 MM (X2), 4.5 X 60 MM) WERE IMPLANTED IN THE SUPERFICIAL FEMORAL ARTERY. THE PATIENT HAD CALF PAIN AND IN-STENT RESTENOSIS IN ALL THREE STENTS ON (B)(6) 2016. LASER ATHERECTOMY AND BALLOON ANGIOPLASTY WERE PERFORMED. THE CONDITION RESOLVED. NO ADDITIONAL INFORMATION WAS PROVIDED.
Patient problems: Pain; Stenosis
MAUDE report 5880642 ↗
Other STENT, SUPERFICIAL FEMORAL ARTERY devices
- EverFlex™ EVD35-06-150-120Covidien LP · STENT, SUPERFICIAL FEMORAL ARTERY1 death110 reports
- SUPERA S-60-150-120-P6Abbott Vascular Inc. · STENT, SUPERFICIAL FEMORAL ARTERY108 reports
- SUPERA S-55-150-120-P6Abbott Vascular Inc. · STENT, SUPERFICIAL FEMORAL ARTERY88 reports
- LifeStent® Solo Vascular Stent EX062003CLBard Peripheral Vascular, Inc. · STENT, SUPERFICIAL FEMORAL ARTERY80 reports
- BioMimics 3D Vascular Stent System 144700-12Veryan Medical Limited · Stent, Superficial Femoral Artery74 reports
- SUPERA S-50-120-120-P6Abbott Vascular Inc. · STENT, SUPERFICIAL FEMORAL ARTERY55 reports
- EverFlex™ EVD35-07-060-120Covidien LP · STENT, SUPERFICIAL FEMORAL ARTERY1 recall5 reports
- EverFlex™ EVD35-07-120-120Covidien LP · STENT, SUPERFICIAL FEMORAL ARTERY1 recall5 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page